158 related articles for article (PubMed ID: 38237804)
21. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
Duddy M; Wilkinson C; Medhurst S; Rhys K
Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
[TBL] [Abstract][Full Text] [Related]
22. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
23. Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
Reyes S; Cunningham AL; Kalincik T; Havrdová EK; Isobe N; Pakpoor J; Airas L; Bunyan RF; van der Walt A; Oh J; Mathews J; Mateen FJ; Giovannoni G
J Neuroimmunol; 2021 Aug; 357():577627. PubMed ID: 34139567
[TBL] [Abstract][Full Text] [Related]
24. Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS.
Corboy JR; Weinshenker BG; Wingerchuk DM
Neurology; 2018 Jun; 90(24):1106-1112. PubMed ID: 29685920
[TBL] [Abstract][Full Text] [Related]
25. 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.
Sanmartí R; García-Rodríguez S; Álvaro-Gracia JM; Andreu JL; Balsa A; Cáliz R; Fernández-Nebro A; Ferraz-Amaro I; Gómez-Reino JJ; González-Álvaro I; Martín-Mola E; Martínez-Taboada VM; Ortiz AM; Tornero J; Marsal S; Moreno-Muelas JV
Reumatol Clin; 2015; 11(5):279-94. PubMed ID: 26051464
[TBL] [Abstract][Full Text] [Related]
26. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
[TBL] [Abstract][Full Text] [Related]
27. Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.
Filippi M; Amato MP; Centonze D; Gallo P; Gasperini C; Inglese M; Patti F; Pozzilli C; Preziosa P; Trojano M
J Neurol; 2022 Oct; 269(10):5382-5394. PubMed ID: 35608658
[TBL] [Abstract][Full Text] [Related]
28. Consensus document on the management of hyperkalemia.
Ortiz A; Galán CDA; Carlos Fernández-García J; Cerezo JG; Ochoa RI; Núñez J; Gutiérrez FP; Navarro-González JF
Nefrologia (Engl Ed); 2023; 43(6):765-782. PubMed ID: 38169239
[TBL] [Abstract][Full Text] [Related]
29. Toward a Shared-Care Model of Relapsing-Remitting Multiple Sclerosis: Role of the Primary Care Practitioner.
Oh J; Gagné-Brosseau MS; Guenette M; Larochelle C; Lemieux F; Menon S; Morrow SA; Poliquin-Lasnier L; Roy-Hewitson C; Rush C; Trudelle AM; Giacomini PS
Can J Neurol Sci; 2018 May; 45(3):304-312. PubMed ID: 29756588
[TBL] [Abstract][Full Text] [Related]
30. The evolution of multiple sclerosis disease-modifying therapies: An update for pharmacists.
Edinger A; Habibi M
Am J Health Syst Pharm; 2024 Jan; 81(2):37-55. PubMed ID: 37777869
[TBL] [Abstract][Full Text] [Related]
31. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
32. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
[TBL] [Abstract][Full Text] [Related]
33. Spanish consensus on the use of natalizumab (Tysabri®)-2013.
Fernández O; García-Merino JA; Arroyo R; Álvarez-Cermeño JC; Izquierdo G; Saiz A; Olascoaga J; Rodríguez-Antigüedad A; Prieto JM; Oreja-Guevara C; Hernández MA; Moral E; Meca J; Montalbán X
Neurologia; 2015 Jun; 30(5):302-14. PubMed ID: 24360652
[TBL] [Abstract][Full Text] [Related]
34. Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
Ha-Vinh P; Nauleau S; Clementz M; Régnard P; Sauze L; Clavaud H
Presse Med; 2019 Jan; 48(1 Pt 1):e1-e19. PubMed ID: 30528148
[TBL] [Abstract][Full Text] [Related]
35. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
36. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
[TBL] [Abstract][Full Text] [Related]
37. Vaccinations in patients with multiple sclerosis: A Delphi consensus statement.
Riva A; Barcella V; Benatti SV; Capobianco M; Capra R; Cinque P; Comi G; Fasolo MM; Franzetti F; Galli M; Gerevini S; Meroni L; Origoni M; Prosperini L; Puoti M; Scarpazza C; Tortorella C; Zaffaroni M; Moiola L
Mult Scler; 2021 Mar; 27(3):347-359. PubMed ID: 32940128
[TBL] [Abstract][Full Text] [Related]
38. Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part II: Obstetric Antiphospholipid Syndrome and Special Situations.
Cáliz Cáliz R; Díaz Del Campo Fontecha P; Galindo Izquierdo M; López Longo FJ; Martínez Zamora MÁ; Santamaria Ortiz A; Amengual Pliego O; Cuadrado Lozano MJ; Delgado Beltrán MP; Ortells LC; Pérez ECC; Rego GD; Corral SG; Varela CF; López MM; Nishishinya B; Navarro MN; Testa CP; Pérez HS; Silva-Fernández L; Taboada VMM
Reumatol Clin (Engl Ed); 2020; 16(2 Pt 2):133-148. PubMed ID: 30686569
[TBL] [Abstract][Full Text] [Related]
39. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.
Montalban X; Gold R; Thompson AJ; Otero-Romero S; Amato MP; Chandraratna D; Clanet M; Comi G; Derfuss T; Fazekas F; Hartung HP; Havrdova E; Hemmer B; Kappos L; Liblau R; Lubetzki C; Marcus E; Miller DH; Olsson T; Pilling S; Selmaj K; Siva A; Sorensen PS; Sormani MP; Thalheim C; Wiendl H; Zipp F
Eur J Neurol; 2018 Feb; 25(2):215-237. PubMed ID: 29352526
[TBL] [Abstract][Full Text] [Related]
40. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
